Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
13-cis-retinoic acid + temozolomide
- Development stage
- Unknown
- Lead developer
- North American Brain Tumor Consortium
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of 13-cis-retinoic acid (cRA) and temozolomide (TMZ). 13-cis-retinoic acid is a metabolite of Vitamin A that induces cell differentiation, apoptosis, and inhibits cell proliferation. Temozolomide is an oral alkylating agent. This combination has been studied primarily for the treatment of recurrent malignant gliomas, showing improved progression-free survival compared to single-agent treatments in some clinical trials.
- Other names
- cRA + TMZisotretinoin + temozolomideaccutane + temozolomide
02
Targets
RXRA (Retinoid X receptor alpha)RARA (Retinoic acid receptor alpha)DNA
Beyond the preview
Go deeper on 13-cis-retinoic acid + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 13-cis-retinoic acid + temozolomide.